What does HOPE stand for?

Commentary: The findings of this study are the same as those seen in the Heart Outcomes Prevention Evaluation trial, the Norwegian Vitamin Trial, and the Vitamin Intervention for Stroke Prevention trial.

Previous studies such as the Heart Outcomes Prevention Evaluation Trial (HOPE) demonstrated that angiotensin converting enzyme (ACE) inhibitors such as ramipril reduce cardiovascular death, myocardial infarction, strokes and heart failure in high risk individuals.

Canadian researchers gave more than 5,500 people with heart disease or diabetes either a daily placebo or a combination of folic acid (2,500 mcg), vitamin B-6 (50 mg), and vitamin B-12 (1,000 mcg) as part of the Heart Outcomes Prevention Evaluation (HOPE-2) trial.

Results from the Heart Outcomes Prevention Evaluation (HOPE) study was to be published in the Jan.

Based on results obtained from the Heart Outcomes Prevention Evaluation (HOPE) Study published in the March 25, 2002 issue of Circulation(1), the patent approval covers the ability of the AspirinWorks(R) Test Kit* to assess a patient's resistance to the anti-clotting effects of aspirin and also to assess the risk of a cardiovascular event (heart attack or stroke) in patients taking aspirin.

Research: The extended Heart Outcomes Prevention Evaluation (HOPE-TOO) trial studied 9541 heart disease patients, who were administered either angiotensin-converting enzyme (ACE) inhibitor ramipril or vitamin E.

14) The Heart Outcomes Prevention Evaluation (HOPE) study (15) indicated a 25% reduction of cardiovascular death, stroke, and myocardial infarction in high-risk patients given ramipril.

In the best study done to date, vitamin E supplements failed to cut the risk of heart disease or stroke, say the authors of the Heart Outcomes Prevention Evaluation (HOPE).